Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash from Financing Activities (2016 - 2025)

Perspective Therapeutics' Cash from Financing Activities history spans 15 years, with the latest figure at $213000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 66.08% year-over-year to $213000.0; the TTM value through Sep 2025 reached $10.7 million, down 96.32%, while the annual FY2024 figure was $289.4 million, 36764.33% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $213000.0 at Perspective Therapeutics, up from $132000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $166.3 million in Q1 2024 and bottomed at -$80000.0 in Q1 2023.
  • The 5-year median for Cash from Financing Activities is $348500.0 (2023), against an average of $25.5 million.
  • The largest annual shift saw Cash from Financing Activities soared 208010.0% in 2024 before it crashed 99.89% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $28000.0 in 2021, then changed by 0.0% to $28000.0 in 2022, then skyrocketed by 1157.14% to $352000.0 in 2023, then decreased by 1.99% to $345000.0 in 2024, then tumbled by 38.26% to $213000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Cash from Financing Activities are $213000.0 (Q3 2025), $132000.0 (Q2 2025), and $10.0 million (Q1 2025).